Our verdict is Benign. Variant got -10 ACMG points: 0P and 10B. BA1BP4BS3_Supporting
This summary comes from the ClinGen Evidence Repository: The c.423-4del variant in APC is an intronic variant which results in the deletion of adenine at position -4 of intron 4. The highest allele frequency is 5.48% in gnomAD v3.1.2, which is higher than the ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel (HCCP VCEP) threshold for BA1 (≥ 0.1%). RNA assays showed no splicing mutation, indicating that this variant does not impact protein function (BS3_Supporting; PMID22447671). Finally, the results from ≥2 in silico splicing predictors support that this variant does not affect splicing (BP4). In summary, this variant meets the criteria to be classified as Benign for FAP based on the ACMG/AMP criteria applied, as specified by the HCCP VCEP: BA1, BS3_Supporting, BP4. (VCEP specifications version 1; date of approval: 12/12/2022). LINK:https://erepo.genome.network/evrepo/ui/classification/CV181781/MONDO:0021056/089
APC (HGNC:583): (APC regulator of WNT signaling pathway) This gene encodes a tumor suppressor protein that acts as an antagonist of the Wnt signaling pathway. It is also involved in other processes including cell migration and adhesion, transcriptional activation, and apoptosis. Defects in this gene cause familial adenomatous polyposis (FAP), an autosomal dominant pre-malignant disease that usually progresses to malignancy. Mutations in the APC gene have been found to occur in most colorectal cancers, where disease-associated mutations tend to be clustered in a small region designated the mutation cluster region (MCR) and result in a truncated protein product. [provided by RefSeq, Jun 2022]
Laboratory of Diagnostic Genome Analysis, Leiden University Medical Center (LUMC)
-
- -
Likely benign, no assertion criteria provided
research
Mayo Clinic Laboratories, Mayo Clinic
-
- -
Benign, no assertion criteria provided
clinical testing
Clinical Genetics, Academic Medical Center
-
- -
Likely benign, criteria provided, single submitter
clinical testing
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital
Aug 15, 2023
- -
Benign, no assertion criteria provided
clinical testing
Genome Diagnostics Laboratory, University Medical Center Utrecht
-
- -
Hereditary cancer-predisposing syndrome Benign:5
Benign, criteria provided, single submitter
curation
Sema4, Sema4
Jan 30, 2020
- -
Benign, criteria provided, single submitter
clinical testing
GeneDx
Mar 27, 2014
The variant is found in COLO-HEREDIC panel(s). -
Benign, criteria provided, single submitter
clinical testing
Ambry Genetics
Jul 07, 2020
This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. -
Likely benign, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Jul 13, 2017
- -
Benign, criteria provided, single submitter
clinical testing
Color Diagnostics, LLC DBA Color Health
Mar 18, 2016
- -
not provided Uncertain:1Benign:3
Likely benign, no assertion criteria provided
clinical testing
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen
-
- -
Uncertain significance, no assertion criteria provided
clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System
-
- -
Benign, criteria provided, single submitter
clinical testing
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden
Nov 03, 2021
- -
Likely benign, no assertion criteria provided
clinical testing
Genome Diagnostics Laboratory, Amsterdam University Medical Center
The c.423-4del variant in APC is an intronic variant which results in the deletion of adenine at position -4 of intron 4. The highest allele frequency is 5.48% in gnomAD v3.1.2, which is higher than the ClinGen InSiGHT Hereditary Colorectal Cancer/Polyposis Variant Curation Expert Panel (HCCP VCEP) threshold for BA1 (0.1%). RNA assays showed no splicing mutation, indicating that this variant does not impact protein function (BS3_Supporting; PMID22447671). Finally, the results from more than or equal to 2 in silico splicing predictors support that this variant does not affect splicing (BP4). In summary, this variant meets the criteria to be classified as Benign for FAP based on the ACMG/AMP criteria applied, as specified by the HCCP VCEP: BA1, BS3_Supporting, BP4. (VCEP specifications version 1; date of approval: 12/12/2022). -
Benign, criteria provided, single submitter
clinical testing
Invitae
Jan 06, 2024
- -
Benign, criteria provided, single submitter
clinical testing
Myriad Genetics, Inc.
Feb 23, 2024
This variant is considered benign. This variant is intronic and is not expected to impact mRNA splicing. -
Gastric cancer;C0346629:Colorectal cancer;C1851124:Desmoid disease, hereditary;C2239176:Hepatocellular carcinoma;C2713442:Familial adenomatous polyposis 1;C4749917:Gastric adenocarcinoma and proximal polyposis of the stomach Benign:1
Likely benign, criteria provided, single submitter
clinical testing
Fulgent Genetics, Fulgent Genetics
Jan 13, 2022
- -
APC-related disorder Benign:1
Benign, criteria provided, single submitter
clinical testing
PreventionGenetics, part of Exact Sciences
Nov 07, 2023
This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). -